Estudo mostra que um tratamento muito mais curto para doença de Chagas pode ter a mesma eficácia e ser significativamente mais seguro

Barcelona/Rio de Janeiro – 14 de março de 2019
Os resultados podem ajudar a eliminar uma das barreiras à implementação do tratamento em larga escala e renovar as esperanças para as pessoas com doença de Chagas
Um tratamento com duração de apenas duas semanas para pacientes adultos com doença de Chagas crônica demostrou, comparado com placebo, ter eficácia semelhante e efeitos colaterais significativamente menores do que o tratamento padrão com duração de oito semanas, de acordo com os resultados de um estudo clínico realizado na Bolívia sob a coordenação da iniciativa Medicamentos para Doenças Negligenciadas (DNDi).

Un estudio muestra que un tratamiento más corto para la enfermedad de Chagas puede ser igual de eficaz y mucho más seguro

Barcelona/Río de Janeiro – 14 de marzo de 2019
Los resultados pueden ayudar a eliminar una de las barreras para ampliar el tratamiento y aportan esperanza a los pacientes con Chagas
Un tratamiento de dos semanas para pacientes adultos con Chagas crónico muestra, comparado con placebo, una eficacia similar y un número significativamente menor de efectos adversos que el tratamiento estándar de ocho semanas de duración, según los resultados de un ensayo clínico en Bolivia, liderado por la iniciativa “Drugs for Neglected Diseases” (DNDi).

Study shows dramatically shorter treatment for Chagas disease could be just as effective, and significantly safer

Barcelona/Rio de Janeiro – 14 March 2019
Results could help remove one of the barriers to treatment scale up and bring new hope for people with Chagas disease
A two-week treatment course for adult patients with chronic Chagas disease showed, when compared to placebo, similar efficacy and significantly fewer side effects than the standard treatment duration of eight weeks, according to the results of a clinical trial in Bolivia led by DNDi.

SADI 2019

9-11 May 2019
Tucuman, Argentina

  • Sergio Sosa-Estani, Head of Chagas Clinical Programmes – presentation of the BENDITA trial results and the benznidazole monotherapy strategy

MSF Scientific Days

9-10 May 2019
London, UK

  • Fabiana Barreira, Chagas Senior Clinical Manager – presentation of the BENDITA trial for Chagas disease

MSF Scientific Day Argentina

4 April 2019
Argentina

  • Fabiana Barreira, Chagas Senior Clinical Manager – presentation of the BENDITA trial for Chagas disease

R&D Portfolio Update February 2019: DNDi Chagas disease programme

A Phase II study of new benznidazole regimens was completed in 2018 with results coming in 2019. A Phase II study of fexinidazole, a new drug being tested for Chagas, completed patient recruitment in 2018. New diagnosis and treatment access projects were launched in Guatemala and Brazil, and the project in Colombia showed major increases in people tested in pilot areas.

XV Chagas disease workshop – ISGlobal

14 March 2019
Barcelona, Spain

  • Fabiana Barreira, Chagas Senior Clinical Manager – presentation on the results of the BENDITA study
  • Isabela Ribeiro, Head of Dynamic Portfolio Unit – presentation on the results of the fexinidazole clinical trials for Chagas disease

Drug discovery for kinetoplastid diseases: future directions

by Rao S, Barrett M, Dranoff G, Farady C, Gimpelewicz C, Hailu A, Jones C, Kelly J, Lazdins-Helds J, Maeser P, Mengel J, Mottram J, Mowbray C, Sacks D, Scott P, Späth G, Tarleton RL, Spector J, Diagana T.

American Chemical Society Infectious Diseases, December 2018